Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04752657
Other study ID # H-40737
Secondary ID 5R01HL141434-03
Status Completed
Phase N/A
First received
Last updated
Start date June 21, 2021
Est. completion date December 28, 2023

Study information

Verified date January 2024
Source Boston University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the electronic Framingham Heart Study (eFHS), the investigators developed and deployed a mobile app to collect cardiovascular risk factors and event data and test them against cardiovascular data collected in the Framingham research clinic for the FHS. Participants enrolled in eFHS receive a series of digital surveys modules to complete on a regularly occurring schedule. The objective of the planned randomized trial is to test the effect of administering half of survey modules every 2 weeks versus all survey modules every 4 weeks on improving participants' response rates. There will be 4 survey periods. Period 1 encompasses all survey modules administered from baseline up to week 8 (19 surveys/tasks per participant); period 2 from week 8 up to week 16 (18 surveys/tasks per participant); period 3 from week 16 up to week 24; period 4 from week 24 (16 surveys/tasks per participant).


Description:

Participants in eFHS are invited to enroll from the FHS Offspring and Omni Group 1 Cohorts during the in-person examination 10/5 at the FHS Research Center in Framingham, Massachusetts (MA), USA or remotely from home after the in-person examination. All eFHS participants have the eFHS myDataHelps mobile app (developed by FHS investigators with CareEvolution our industry partner) installed on their smartphone. The eFHS app allows communication with participants through notifications and data collection. Participants are asked to answer health surveys administered through the app. Survey assessments will include 6 modules: cognition, pain, mood, physical function and performance, physical activity, and events. The interventions are defined by the patterns of administration of survey modules to the experimental and control groups. The administration of the cognition, pain, mood, and psychosocial modules follow the same pattern for both groups. However, the administration of the physical function, physical activity, and events modules is delayed by 2 weeks in the experimental group as compared to the control group.


Recruitment information / eligibility

Status Completed
Enrollment 492
Est. completion date December 28, 2023
Est. primary completion date December 28, 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Invited to enroll from the FHS Offspring and Omni Group 1 Cohorts during the in-person examination 10/5 at the FHS Research Center - English speaking - English language reading proficiency - Owns an iPhone with compatible iOS (version 10.0 or higher) or Android (version 5.0 or higher) - Residence in the United States - Provision of permissions for notifications and data sharing with the Research Center - Provision of signed and dated informed consent (within the eFHS mobile app) Exclusion Criteria: - Limited and non-readers

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Delayed administration of survey modules
The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks
Regular administration of survey modules
The physical function, physical activity, and events survey modules are administered according to the regular pattern

Locations

Country Name City State
United States Framingham Heart Study Framingham Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Boston University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of surveys/tasks returned in period 1 Proportion of surveys/task returned per participant (partially or fully completed) from baseline, up to week 8, will be documented on the eFHS app. baseline, up to week 8
Primary Proportion of surveys/tasks returned in period 2 Proportion of surveys/task returned per participant (partially or fully completed) from week 8, up to week 16, will be documented on the eFHS app. week 8, up to week 16
Primary Proportion of surveys/tasks returned in period 3 Proportion of surveys/task returned per participant (partially or fully completed) week 16, up to week 24, will be documented on the eFHS app. week 16, up to week 24
Primary Proportion of surveys/tasks returned in period 4 Proportion of surveys/task returned per participant (partially or fully completed) week 24, to completion of study usually 26 weeks, will be documented on the eFHS app. week 24, to completion of study usually 26 weeks
Secondary Proportion of questions/task completed per participant in period 1 Proportion of questions/task completed per participant from all survey modules administered from baseline to week 8, will be documented on the eFHS app. baseline, up to week 8
Secondary Proportion of questions/task completed per participant in period 2 Proportion of questions/task completed per participant from week 8 to week 16, will be documented on the eFHS app. week 8, up to week 16
Secondary Proportion of questions/task completed per participant in period 3 Proportion of questions/task completed per participant from week 16 to week 24, will be documented on the eFHS app. week 16, up to week 24
Secondary Proportion of questions/task completed per participant in period 4 Proportion of questions/task completed per participant from week 24 to study completion, will be documented on the eFHS app. week 24, to completion of study usually 26 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)